NeuroMetrix

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. It focuses on the sale of medical equipment and consumables. Its products include DPNCheck, Quell, and ADVANCE system. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroMetrix reports Q2 revenue decline but shows promise in Quell line

NeuroMetrix faced revenue decline due to DPNCheck product line, offset by strong growth in the Quell product line.
Efficient cost management reflected in a solid gross margin rate of 64% and reduced operating expenses.
The company maintains a healthy financial position with significant working capital and liquid assets.
Strategic review aims to enhance shareholder value and explore new growth avenues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

WOBURN, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023.

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023

WOBURN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023. This live, interactive, online event will give shareholders and the investment community the opportunity to interact in real time with the Company's Chairman and Chief Executive Officer, Dr. Shai N. Gozani. Dr. Gozani will present business highlights and recent developments, including the evolution of its Quell® neuromodulation technology. He will be available for questions from conference participants.

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices.

NeuroMetrix Reports Q2 2023 Business Highlights

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on July 27, 2023.

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

WOBURN, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell® Fibromyalgia, which is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the symptoms of fibromyalgia.

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

WOBURN, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people with diabetes.

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

WOBURN, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK. The scientific poster was titled "Abnormal combined diabetic peripheral neuropathy (DPN)-check and SUDOSCAN results predict all-cause mortality in people with diabetes: The Sheffield prospective study."

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN): A proof-of-concept, placebo-controlled, randomized clinical trial (RCT)." The abstract will be published at the 2023 American Society of Clinical Oncology (ASCO) annual meeting to take place June 2-6 in Chicago, IL. The principal investigator is Dr. Jennifer Gewandter of the University of Rochester School of Medicine and Dentistry. The trial leveraged the National Cancer Institute (NCI) Community Oncology Research Program (NCORP).

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

NeuroMetrix, Inc. (NASDAQ:NURO ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Thomas Higgins - SVP, CFO & Treasurer Shai Gozani - Founder, Chairman, CEO, President & Secretary Conference Call Participants Operator Good morning, and welcome to the NeuroMetrix First Quarter 2023 Earnings Call. My name is Levay, and I'll be your moderator on the call.

NeuroMetrix, Inc. (NURO) Q1 2023 Earnings Call Transcript

WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

NeuroMetrix Reports Q1 2023 Financial Results

WOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on May 3, 2023 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented.

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

NeuroMetrix, Inc. (NASDAQ:NURO ) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Thomas Higgins - Senior VP, CFO & Treasurer Shai Gozani - Founder, Chairman, CEO, President & Secretary Conference Call Participants Jarrod Cohen - Cohen Operator Good morning, and welcome to the NeuroMetrix Fourth Quarter and Full Year 2022 Earnings Call. My name is Latanya, and I will be your moderator on the call.

NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript

WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on February 23, 2023 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

Point-of-care technology helps healthcare providers rapidly identify at-risk patients Point-of-care technology helps healthcare providers rapidly identify at-risk patients

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania. Quell Fibromyalgia is a wearable neuromodulation technology that is the first and only FDA authorized medical device to help reduce the symptoms of fibromyalgia. Conference attendees are encouraged to visit the Company's booth #1745 for a demonstration and to review prescribing details for fibromyalgia patients.

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. (NASDAQ:NURO ) Q3 2022 Earnings Conference Call October 20, 2022 8:00 AM ET Company Participants Thomas Higgins - SVP & CFO Shai Gozani - CEO Conference Call Participants Jarrod Cohen - JM Cohen & Company William Church - TGRA Capital Operator Good morning, and welcome to the NeuroMetrix Third Quarter 2022 Earnings Call. My name is Michelle and I will be your moderator on the call.

NeuroMetrix, Inc. (NURO) Q3 2022 Earnings Call Transcript

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

NeuroMetrix Reports Q3 2022 Financial Results

WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on Oct 20, 2022 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

DPNCheck is a screening product sold to MA insurers which gives better member health outcomes, lower cost, and increased revenue for MA insurers. The product has consistently grown >20%. Discontinuation of Quell marketing in 2018 is masking the strong, underlying growth in DPNCheck. The result is rev growth is now accelerating.

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell® device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021.

NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

NeuroMetrix, Inc. (NASDAQ:NURO ) Q2 2022 Earnings Conference Call July 21, 2022 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - President and Chief Executive Officer Operator Good morning and welcome to the NeuroMetrix Second Quarter 2022 Earnings Call. My name is Michelle and I will be your moderator on the call.

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2022 Results - Earnings Call Transcript

WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

News for NeuroMetrix Stock (NURO)